Biocryst Pharmaceuticals (BCRX) Operating Expenses (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Operating Expenses came in at $858.0 million in Q1 2026, up 590.24% YoY from $124.3 million in Q1 2025, and up 487.0% on a QoQ basis from $146.2 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Operating Expenses (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Operating Expenses data on file, last reported at $858.0 million in Q1 2026.
- Quarterly Operating Expenses rose 590.24% year-over-year to $858.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 169.51% YoY) and the FY2025 annual result came in at $533.8 million, up 17.78% from the prior year.
- Operating Expenses improved to $858.0 million in Q1 2026, from $146.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $858.0 million in Q1 2026 to a low of $93.3 million in Q3 2022.
- A 5-year average of $158.8 million and a median of $109.4 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses fell 2.69% — and 2026, when it surged 590.24%.
- Tracing BCRX's Operating Expenses over 5 years: stood at $125.9 million in 2022, then rose by 8.12% to $136.1 million in 2023, then fell by 0.02% to $136.0 million in 2024, then advanced by 7.44% to $146.2 million in 2025, then surged by 487.0% to $858.0 million in 2026.
- The last three Operating Expenses figures came in at $858.0 million (Q1 2026), $146.2 million (Q4 2025), and $129.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 119.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.79 Mn |
| Mar 31, 2026 | 858.01 Mn |
| Dec 31, 2025 | 146.17 Mn |
| Sep 30, 2025 | 129.80 Mn |
| Jun 30, 2025 | 133.57 Mn |
| Mar 31, 2025 | 124.31 Mn |
| Dec 31, 2024 | 136.04 Mn |
| Sep 30, 2024 | 109.39 Mn |
| Jun 30, 2024 | 100.57 Mn |
| Mar 31, 2024 | 107.25 Mn |
| Dec 31, 2023 | 136.07 Mn |
| Sep 30, 2023 | 98.66 Mn |
| Jun 30, 2023 | 103.19 Mn |
| Mar 31, 2023 | 97.19 Mn |
| Dec 31, 2022 | 125.86 Mn |
| Sep 30, 2022 | 93.27 Mn |
| Jun 30, 2022 | 100.25 Mn |
| Mar 31, 2022 | 99.88 Mn |
| Dec 31, 2021 | 99.34 Mn |
| Sep 30, 2021 | 85.58 Mn |